Compare AbCellera Biologics Inc (ABCL) vs Ambarella Inc (AMBA) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Ambarella (AMBA) trades at $79.73, up 1.75% with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant $800M+ long-term edge AI agreement with Hanwha. Revenue grew 16.9% year-over-year in Q1 2027 to $100.4M, though the company remains unprofitable with a -17.18% net income margin. Analyst sentiment is strongly positive with 58% buy ratings and a $108.67 consensus price target representing 36% upside potential.

Ambarella presents a compelling growth story in edge AI with strong analyst support and recent business momentum, but faces execution risks in transitioning to profitability. The stock's current valuation at 8.47x sales appears justified given the company's positioning in the rapidly expanding physical AI market, though investors should monitor progress toward sustainable profitability and competitive pressures in the semiconductor space.